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The Role of the Clinical Nurse Leader in Reintroducing and Sustaining a Successful 
Cancer Risk Assessment Program in a Community Hospital Setting 
 With the advancements in cancer genetics and risk identification of both familial 
and genetically predisposed individuals, the importance of integrating risk stratification 
into practice is more important than ever. While some patients may not be able to avoid 
an inevitable cancer diagnosis, understanding risk can enhance adherence to lifestyle 
changes, screening practices, and even prophylactic prevention strategies.  
The American Cancer Society (ACS) has amended current guidelines concerning 
the screening and treatment of women at average risk for breast cancer to begin yearly 
screening mammograms at age 45 (as cited in Oeffinger et al., 2015). The opportunity to 
screen beginning at age 40–44 is optional based on self-determination and consult with a 
physician, at which point the recommendation of annual mammography is based on the 
level of cancer risk for the individual. However, evidence demonstrates that of 90% of 
women who qualified as “high risk” for consideration of BRCA testing [as defined by the 
United States Preventative Services Task Force (USPSTF)] that shared this information 
with their primary care provider, only 20% were referred for genetic counseling (Cragun 
& Pal, 2013). This indicates that significant portions of the population that may be at 
increased risk are unidentified, and many clinicians in primary care are unaware of the 
familial characteristics that denote an individual as high risk. A 2012 study states that 
women as young as 25 who are known to have a BRCA mutation are recommended to 
begin screening mammography annually (Pal & Vadaparampil, 2012), an age far outside 
of the parameters recommended by the ACS. For individuals who may not be aware of 
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their risk and are following recommendations based on ACS guidelines, screening may 
be commencing later than it should.  
Second to age, a strong family history of cancer diagnoses is the most significant 
indicator of determining an individual’s risk for development of the disease (Amir, 
Freedman, Seruga, & Evans, 2010) and hereditary conditions account for roughly five to 
10% of all cancers, increasing an affected individual’s risk of developing cancer in their 
lifetime over the general population (“Integrating Genetic”, 2008). Amir et al. (2010) go 
on to state that even without an identified genetic mutation, those individuals who present 
with an increased 5-year risk of developing breast cancer, based on family history 
algorithmic risk assessment models, benefit from enhanced screening, lifestyle changes, 
and preventative pharmacological and/or surgical interventions. The incentive, then, is to 
pursue prevention as well as curable detection; earlier diagnosis and staging that 
increases treatment options and improves prognosis (Caplan, 2014). Since individuals 
that may be susceptible to the development of cancer due to hereditary factors do not 
present with phenotypic clues, the importance of obtaining a comprehensive family 
history is the first step in identifying high-risk patients. Therefore, reinstating a 
comprehensive cancer risk assessment (CRA) program within the community-based 
breast center will potentially increase the rate of identification of moderate to high-risk 
patients leading to improved outcomes. 
Clinical Leadership Theme 
The most appropriate theme for the Clinical Nurse Leader (CNL) role in the 
development of this project is Care Environment Management. Embedded within this 
curricular element is the CNL role of Team Manager, which the CNL will demonstrate 
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by identifying both clinical and financial outcomes that improve patient safety, timeliness 
and quality of care, as well as improving efficiency and appropriateness of care delivery 
thereby increasing downstream revenue for the organization.  
Statement of the Problem 
In light of primary care provider lack of knowledge in adequately identifying 
moderate to high-risk cancer patients, a comprehensive CRA program would serve to 
identify such patients as well as provide clinician education on cancer syndrome 
characteristics. A previously grant funded CRA program within the microsystem was 
able to provide this service, but has subsequently been terminated due to institutional 
factors. This has led to a sharp decline in the number of patients identified and 
appropriately referred for services to manage their individual risk.  
Project Overview  
The project goal of reinstating the CRA program, with the intent to analyze and 
overcome barriers that led to the elimination of the previous program, will be to close the 
gap in at-risk patient identification and ensure proper implementation and sustainability. 
This will demonstrate benefit both to the community as well as the institution by 
potentially decreasing the impact of late stage cancer incidence while simultaneously 
setting the institution apart as a unique provider of such services and increasing 
downstream revenue. The project deliverable will be a comprehensive analysis of the 
program, which will be presented to both clinical and administrative stakeholders in 
August 2017. This analysis will include the presentation of current evidence to 
demonstrate the validity and need of CRA within the setting, a cost-benefit analysis of a 
new CRA program, and multiple staff infrastructure alternatives at each stage (initial 
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staffing needs with additional staff added in accordance with program growth), as well as 
recommendations for implementation. The specific aim at this stage of project 
development is to demonstrate evidence that incentivizes each stakeholder to approve the 
program implementation. This is a critical element required to achieve the global aim of 
increasing identification, stratification, and appropriate referral pathways for patients 
within the community that are at moderate to high-risk for genetic or familial cancer 
syndromes. 
Rationale 
Within the microsystem evaluated for this project, a community-based breast 
cancer clinic, a previously grant-funded cancer risk assessment and genetic evaluation 
(CRA/GE) program led by a Nurse Practitioner-Genetic Counselor (NP-GC) was 
analyzed. A review of historical data from the program indicates that the NP-GC was 
able to identify and consult with 2,679 patients (an average of 446.5 each year) over the 
program’s six-year run (Mott & Coleman, 2015). Of this population, 230 patients 
underwent genetic counseling and 12 patients presented with genetic mutations from 
subsequent testing. With the conclusion of grant funding in 2014, the program was 
unsustainable due to lack of resources; human, financial, and time and the current 
program is primarily a referral-based genetic evaluation clinic. In 2015, the program 
received 340 referrals resulting in 221 consultations, indicating a 50% decrease in high-
risk consultations. This represents the gap in care that was previously provided and the 
evidence of the need for the project. 
Additional data analysis includes a current microsystem assessment using the 
Dartmouth Institute Clinical Microsystem workbooks, assessing the 5 Ps (purpose, 
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patients, professionals, processes, and patterns), a SWOT analysis (Appendix A), and 
stakeholder interviews, all of which were evaluated to conduct a root-cause analysis to 
identify causes for previous lack of sustainability and potential barriers to future 
implementation (Appendix B).  
Cost Analysis 
 The projected costs associated with the program are primarily related to staffing. 
Several possibilities will be presented, with the best option for the institution to be 
determined by the stakeholders. The first cost decision will be to determine if an RN or 
an NP should direct the program. The average salary for an RN in the organization is 
$50.00 per hour with an annual salary of $104,000 plus benefits [add the industry average 
of 30% of salary ($31,200) + $104,000 = $135,200]. The average salary for an NP is 
$63.00 per hour with an annual salary of $131,040 plus benefits for a total of 
$170,352.00 (P. Olson, personal communication, June 20, 2017). An important fact to 
remember during the decision making process is that an NP has the ability to bill for their 
services, thereby offsetting the cost of salary.  
Since the program will not necessarily require a 1.0 FTE at the outset, based on 
historical patient volume data from the previous CRA program, the program would only 
require a 0.4 FTE. This translates to the part-time reimbursement rate (not including 
benefits) of $41,600 and $52,416 for the RN or NP, respectively. This may be the most 
cost-effective way to implement the program with the intent to add additional hours 
and/or support staff as the program grows. However, anticipating that it may be difficult 
to recruit a quality candidate for a part-time position that is complex in nature, two 
possible solutions justify the hiring of 1.0 FTE. If an RN fills the position, the additional 
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time outside of what is required for the CRA program could be used in the role as nurse 
navigator for patients that have been referred for breast biopsy within the breast-imaging 
center. This would involve patient outreach at time of scheduling, pre- and post- biopsy 
education, delivery of test results, and hand off to the appropriate clinician. Currently, 
this is a role that is not fulfilled within the breast-imaging department and therefore is not 
meeting the standard of practice (American College of Surgeons: Commission on Cancer, 
2016).  
If an NP directs the CRA program, this clinician could fulfill the navigator 
position within breast imaging as well as assist within the cancer survivorship program 
by working alongside the MD in navigating treatment for all patients stratified as high-
risk not appropriate for genetic counseling. As previously mentioned, the NP would also 
have the ability to bill for consult and navigation services, increasing the potential for 
increased revenue. Each of these options is outlined in further detail in the cost-benefit 
analysis (Appendix C). Additional costs consist of education and training expenses, 
genetics and survivorship provider time, office supplies, software upgrades, and a 
computer.  
Methodology 
Recommendations will be made to the stakeholders for program implementation, 
regardless of the staffing choice that is made. Identification of the appropriate change 
theory as well as anticipatory cycles of the Plan, Do, Study, Act (PDSA) model will be 
addressed here.  
This model chosen to guide the stages of this project has been based on Rogers’ 
diffusion of innovation. The five-step process Rogers outlined by which change occurs 
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recognizes the reversible nature and evolution of the change, as opposed to Lippitt’s 
theory, which emphasizes the actions of the change agent rather than the change (as cited 
by Sullivan, 2013). The five steps described in Rogers change theory, as cited by 
Kaminski (2011), begin with the knowledge or awareness of the individual or group to 
the potential new innovation. From there, the second step is where interest is generated 
and information gathering begins in order to inform and encourage participation of 
stakeholders in the change being considered. Based on evaluation of the data, the third 
step is then to make the decision of whether or not to implement the change by 
envisioning the impact in the particular setting. It is at this stage that the CNL will 
present findings to the stakeholders. The fourth step is the actual implementation of the 
innovation followed by the fifth step of confirming the effectiveness of and adoption of 
the change. The fourth and fifth steps will be outlined below. 
The CRA program will be physically situated near the breast-imaging center, 
which is one floor down from the breast cancer center. This is also the site of the previous 
CRA program. The nurse director of the program will initially undergo facility and 
program-specific orientation as well as guided training from the genetics and 
survivorship programs. Upon completion of training, implementation will begin with the 
nurse director soliciting patient involvement, with the defined goal of 5 new patients, in 
risk assessment from the patient population within breast imaging. The goal of this initial 
phase, defined as the first week of the program, is to establish the nurse director’s 
competency in risk stratification and subsequent appropriateness of referral. Additionally, 
this time will be trialed to establish workflows to facilitate patient tracking and follow-up, 
as well as ensure smooth implementation of system software. This will be the data 
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evaluated (either success or failure) to move into the next PDSA cycle. The next one-
week cycle, assuming data points indicated success in the first cycle, will be for the nurse 
director to intake 5-10 new patients from within breast imaging. In each of these phases 
the director will establish contact with each patient and initiate further risk assessment 
and patient/family history utilizing the software currently in use by the genetics program. 
The goal of this cycle will be for the director to successfully triage each referral to either 
the primary care provider for enhanced screening recommendations, genetics, or 
survivorship. The data evaluated will be the accuracy for which each recommendation is 
made.  
After this initial implementation phase, the director will be announced to the 
medical group, as well as external referral sources, as the point of contact for all future 
risk assessment. In addition to this patient source, the director will continue to solicit 
interest from the patient population within breast imaging for additional program 
participation. Successful growth has been demonstrated through this method by the 
previous CRA program. Long-term data that will be evaluated to determine sustainability 
of the program is the percentage increase in; identification of moderate to high risk 
patients; the use of screening, diagnostic, and surgical procedural interventions; as well as 
the tracking of individual patient data that signifies follow up and continuity of care. This 
data is valuable as it demonstrates increased downstream revenue generation from the 
program and increased retention of patients within the medical group. Each of these 
metrics will be documented at the program start date as well as at the 3, 6, and 12 month 
post-implementation dates for comparison and program growth rate.  
 
CNL ROLE IN CANCER RISK ASSESSMENT 10 
 
Data Sources  
Microsystem Assessment 
The microsystem assessment was conducted using a modified workbook as 
provided by the Dartmouth Institute Clinical Microsystems Assessment tools. This initial 
evaluation is critical in understanding the 5Ps of the breast cancer center; purpose, 
patients, professionals, processes, and patterns in order to plan and design a CRA 
program that fits into existing clinical patterns and workflows. This is particularly 
appropriate for this project due to the fact that a previous, similar program has existed in 
this setting and as such, the current stakeholders may be subject to experiential bias as to 
how the program should be designed or, in some cases, if it should be implemented at all. 
This stakeholder bias may also inhibit understanding of current processes and their 
evolution since the ending of the previous program.  
Institutional Data 
 In order to accomplish the goal of demonstrating downstream revenue, the CNL 
student compiled a list of screening, diagnostic, surgical, and consultative services that 
pertain to cancer risk assessment with the assistance of the NP-GC preceptor. This list 
was then submitted to the coding department of the medical group to obtain the net 
reimbursement rates for each CPT coded procedure. This data will be compared against 
the historical data from the previous CRA program, specifically the volume of patients 
that would have been appropriately referred for each procedure. This will demonstrate the 
potential increase in volume and revenue, thereby offsetting the cost of the program. 
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Informational Interviews 
 Initial informational interviews were conducted a year ago during the first 
microsystem assessment. Additional interviews are being conducted as several changes 
have occurred within the organization such as a merger with Providence Health. This was 
deemed necessary to ascertain any shift in position from the stakeholders over the 
passage of time or change in organizational priorities.  
Literature Review 
According to the Community Health Needs Assessment for Sonoma County 
2013-2016, cancer is the leading cause of death for years 2008-2010 and is significantly 
higher than the California rate as well as the Healthy People 2020 target (Sonoma 
County, 2016). The report also indicates that not only does Sonoma County have a higher 
incidence rate than that of the state in all cancers, the specific cancers with the highest 
incidence rates are breast and prostate. This highlights the need, very specifically for this 
community, for enhanced assessment and screening of genetic and epigenetic cancers.  
While the education and active involvement of primary care providers in 
identifying characteristics of familial cancer risk is an important and long-term goal, the 
evidence is also clear in indicating the need for the integration of a comprehensive CRA 
program to be managed by a professional and clinically competent practitioner. Providers 
oftentimes are not aware of the risk indicators within a patient history that warrant further 
assessment, ultimately resulting in the delay of appropriate patient risk stratification and 
intervention. Conversely, with the increasing availability and decreasing costs of large 
panel genetic tests, some providers take it upon themselves to order genetic testing 
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without conducting pre-and post-test counseling as well as not having a full 
understanding of the results. This leads to more confusion, anxiety, and mistrust from the 
patient.  
Two studies included in this review address the impact of delays in detection, 
diagnosis, and treatment of cancers and the outcomes of tumor staging and survivability. 
Two articles address the overuse of genetic testing, factors that affect benefits and harms 
of CRA, and provide evidence to promote the use of qualified risk assessment/genetics 
providers. A fifth article outlines a model of incorporating genetic cancer risk assessment 
in regions that do not have access to a genetic counselor by partnering the community-
based medial group with City of Hope’s Cancer Screening and Prevention Program 
Network (CSPPN). The final item in this review is a PowerPoint presentation given by 
the NP-GC and the CNL student’s USF advisor which outlines the data pertaining to the 
initial CRA/GC program and is included based on it’s relevance to actual evidence as it 
applies to the microsystem setting.  
Delays in Care 
In the first article, Cragun & Pal (2013) identify a delay as the lack of the primary 
care provider’s ability to properly identify high risk patients and provide timely referral 
to risk assessment and counseling. The authors highlight the need for OB/GYN providers 
to become proficient in identifying the risk indicators present within patient personal and 
family histories in order to increase timely referral to enhanced risk assessment and 
screenings.  The second article, a literature review, Caplan (2014) describes delays in 
diagnosis and treatment as attributable to either patient delays (seeking care) or system 
delays (providing care). The focus of the review is to determine the difference in tumor 
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staging and prognosis in the event of either cause of delay. The findings are mixed and an 
important factor is discussed for the heterogeneity of results: the biological characteristics 
of the tumor, whether it is large and palpable or slow-growing, may have more to do with 
outcomes as this presents both the patient and clinician with an identifiable cancer 
symptom. This underscores the importance of weighing personal and family history in 
the event that a patient could be at risk and possibly just asymptomatic.  
Evidence for the Use of CRA and Genetics Specialists 
Nelson et al. (2014) conduct a systematic review of current literature published 
from 2004 to 2013 to update the 2005 United States Preventative Services Task Force 
(USPSTF) recommendations for women at high risk for BRCA1 and/or BRCA2 
mutations and referral for genetic counseling. The authors analyzed the benefits and 
harms of risk assessment, genetic counseling and subsequent testing, and preventative 
therapies as they pertain to patient perceptions of risk, anxiety, and depression. The 
benefits and harms varied relative to risk and the authors go on to state that due to the 
complexity of the process at every stage, the service of risk assessment and referral must 
be highly individualized to minimize adverse outcomes such as inappropriate over 
screening, false positives or negatives, and unnecessary worry or anxiety based on 
inconclusive genetic test results or interpretation.   
In a similar study, Walker, Licqurish, Chiang, Pirotta, and Emery (2015) 
conducted a review of 11 randomized control trials of CRA tools to determine the impact 
they have on clinical utility, screening behaviors, and patient perceptions. Results of the 
review indicated that the use of risk assessment tools did show a benefit in improving 
patient perception of risk; intentions to undergo cancer screenings, and lifestyle changes, 
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the actual evidence of behavioral changes were not present. This study indicates the need 
for dedicated clinician interventions to conduct follow up surveillance on high-risk 
populations to promote enhanced cancer screening behaviors. Both of these studies 
highlight the importance of utilizing a trained clinician in risk assessment and genetics 
when attempting to incorporate a comprehensive CRA program.  
Overcoming Lack of Access 
The microsystem that is the focus of this project is fortunate to have a certified 
genetic counselor already in place as a resource. This is not always the case, particularly 
in the rural community setting. However, location does not negate the need for 
specialized clinicians, nor does it prohibit the establishment of a program without this 
resource on site. MacDonald, Blazer, and Weitzel (2010), members of Clinical Cancer 
Genetics Division at the City of Hope Comprehensive Cancer Center, give detailed 
approaches toward implementing genetic cancer risk assessment programs into the 
community-based setting. By detailing a delivery model based on partnering a 
community-based medical center with an academic institution for technical and 
professional support, the authors provide recommendations for expanding the knowledge 
of City of Hope into more rural environments.  
Microsystem Site-Specific Evidence 
Evaluation of the data from the previous CRA/GE program (Mott & Coleman, 
2015) demonstrates the impact of the program through a community outreach model of 
patient participation and risk identification. Over the 5 year period of active risk 
assessment, the program director was able assess 10,522 patients and provide follow up 
consultation with 2,679 individuals. This illustrates the volume of patient capture that is 
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generated from active patient engagement, not taking into account the potential 
percentage increase through a long-term program goal of primary care provider outreach 
and education. 
Timeline 
The project, with it’s newly defined deliverable, will come to fruition over the 
months of June, July, and early August 2017 (Appendix D). Due to institutional 
constraints in implementing the actual CRA program, the project focus has shifted to one 
in which the business case for the program will be presented as this is more in line with 
the CNL program deadlines. The success of the deliverable will be measured by the 
decision of the stakeholders to move forward with the recommended next steps of 
program adoption.  
The evaluation of the original microsystem assessment will be conducted to 
determine if any significant changes have occurred in the setting from the time of the first 
assessment. Informational interviews will then be conducted as a data source. Next, the 
CNL student will construct a procedural list with corresponding CPT codes and 
reimbursement rates which will then be compared against patient data from the previous 
CRA program to establish potential downstream revenue. A cost-benefit analysis will be 
generated using staffing data from the organization’s human resources department and 
the projected revenue stream previously mentioned. This will then culminate in the 
creation of a business plan and PowerPoint presentation to be presented to the 
multidisciplinary stakeholders during the first week of August.  
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Expected Results 
This program has been one that the clinicians within the breast center have 
wanted to reimplement since it was originally phased out in 2013. The level of buy-in 
from this group, therefore, was assumed at the outset of planning stages and taken into 
consideration when deciding how best to design and implement a new CRA program. 
During the first round of informational interviews that were conducted in the summer of 
2016, the enthusiasm and almost impatience of the clinical stakeholders was evident. 
Based on perspectives from this group, it was hard to understand why this had been met 
with such institutional inertia. In that same time period, informational interviews were 
also conducted with two administrative stakeholders; the director of imaging, and the 
area director of operations for the medical group. Both of these meetings shed a 
significant amount of light on the source of resistance to a new CRA program. 
The director of imaging oversees the radiology department within the hospital as 
well as the outpatient breast-imaging center located in the same building as the breast 
center. During it’s first incarnation, the CRA program was housed within breast imaging 
and conducted by the NP-GC. The program was launched with the design to solicit 
patient participation through the mammography clinic by having the patient fill out a 
tablet-based questionnaire, given by the mammography staff. The program itself was 
successful, however, due to lack of clarity of assigned roles and responsibilities, the 
imaging staff felt burdened by the additional work. Add to this personality conflicts and 
assumptions of willing participation and the environment became toxic. This was all 
explained to the CNL student by the imaging director only after the student had assured 
him that his frank honesty would help in the evaluation of potential impacts of the 
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program and how best to laterally integrate in the future. In a subsequent meeting with 
this same individual conducted on June 20th, 2017, a revised proposal was made of the 
integration of a new role, that of the RN or NP CRA director, within his department to 
oversee the CRA program as well as fill the gap in current patient-centered care by acting 
as the nurse navigator for breast biopsy patients. 
The second administrative stakeholder interview involved the area director of 
operations (ADO) whose oversight is of the medical group service line. It was clear 
during this meeting that the ADO was very aware of the breast clinicians’ desires to bring 
back the CRA program, however, the structure of any communication had been siloed 
between vested parties. Clinical stakeholders did not effectively communicate their ideas 
for methods of implementation nor offer any insights into overcoming conflicts that led 
to the erosion of the previous program. With the responsibility to the financial health of 
the medical group, the ADO could not see the benefit of resurrecting a program that does 
not increase the bottom line. In addition to this, the ADO feels that the NP-GC should be 
able to see more patients during the day and argues that the CRA program will only serve 
as a feeder for the genetics program, which he believes is already overwhelmed.  
The outcomes of theses two interviews have had the most impact on the direction 
and planning of this project. By taking what the director of imaging shared and offering 
him solutions to the conflicts he had to mitigate from the first program, the second 
meeting was very productive. By proposing the solution of a shared FTE with the design 
of the infrastructure to grow along with the program and presenting a cogent plan, the 
director expressed optimism for the program moving forward. The director gained 
additional confidence when the program design was explained to be a stand-alone CRA 
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clinic, which would not place his staff in direct contact with the individuals with whom 
original conflict had arisen. After the interview with the ADO, insight was gained as to 
how best to offset expense in the beginning stages of the program and provided 
inspiration to delve deeper into potential revenue sources for the program as well.  
As the evidence to the benefits of a CRA program on clinical outcomes is 
abundant, there can be no argument against the implementation based on its virtues of 
patient-focused care. However, good intentions and clinical improvements can be 
derailed if not properly introduced and managed. By acting as the liaison between the 
vested parties, the CNL was able to listen to concerns and priorities and integrate the 
shared and individual values in the design and focus of the project. It is for these reasons 
that the expected outcome is to be one of adoption and forward momentum of the 
program implementation.  
Nursing Relevance 
The tools required to effectively evaluate a quality improvement project in the 
clinical setting are numerous. The nurse must have the clinical knowledge to assess 
where a gap in care exists, as well as to determine the interventions that will potentially 
improve outcomes. Secondarily, the nurse must be able to objectively evaluate the 
environment including setting, culture, habits, and external influences, to determine if the 
project will be feasible in that location at that time. In other words, even with the best 
intentions not all projects are a good fit in every microsystem. 
The elements of this project are two-fold. The first is the element of increasing the 
knowledge base within the contexts of hereditary and family history as it pertains to 
cancer risk. Improving the understanding in all nurses, regardless of specialty, of the 
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hallmark characteristics within a patient’s personal or family history that indicate 
potential increased risk facilitates the earlier assessment, identification, and appropriate 
intervention for each individual. As nurses are oftentimes the frontline clinicians that 
conduct extensive histories, this increased level of awareness could help to mitigate 
disease incidence as well as increase curable detection, which often leads to greater 
treatment options and more favorable prognoses.  
The second element is that of objective auditing. This role is critical in expanding 
the credibility of the nurse, as it requires the objective evaluation of the feasibility of an 
improvement being considered and removing bias based on emotion or passion. It is one 
thing to see where there is a gap in care and have the evidence-based solution ready to 
roll out, but if the nurse lacks the ability to identify all the stakeholders at each level of 
involvement, recognize the financial impacts, or assess the climate of the environment 
and its readiness for change even the best quality improvement initiative will hit a 
proverbial wall. The advancement of nursing involves the ability to expand the scope of 
thinking to beyond that of just a front line clinician. The nurse must think in the best 
interest of all vested parties; patients, families, staff, organization, and community.  
Project Summary 
Over the course of a year, the CNL student has revised the original project aim of 
the actual reintroduction of a CRA program to a focus of creating a value proposition 
with the intent to garner administrative and clinical stakeholder support. The clinical 
setting of this evaluation is a midsize community hospital with an accredited cancer 
program and breast center and affiliated medical group/provider network. Since 2016, the 
CNL student conducted a microsystem assessment and developed an action plan to 
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reintroduce a CRA program in a clinically complex and politically challenging work 
environment.  
After completion of initial microsystem and previous CRA program assessments, 
the methods for the future program valuation include several diverse data sources. A 
literature review of similar program establishment was conducted to determine the 
infrastructure needs and develop a proposal which addressee and overcomes the 
personnel and logistical issues related to the first CRA program. A patient pathway 
flowchart was created to differentiate between the future CRA program, the current 
Genetic Evaluation and Management practice, and the Survivorship program (see 
Appendix E). 
A comparison of historical CRA volume to the current patient volume within the 
Genetic Evaluation and Management program revealed a roughly 50% decrease in 
potential high-risk patient capture. The CNL student compiled a list of relevant screening 
and diagnostic procedural codes and associated Medicare net reimbursement rates, which 
were then applied to the potential patient volumes to determine estimated downstream 
revenue. Organization market share (30%) was applied to population data related to high-
risk indicators to demonstrate additional sources of potential revenue. Personal 
communication with the organization human resource department was conducted to 
determine future program clinician and clerical staffing reimbursement rates. This data 
was applied to the standard benefits rate of 30% to calculate staffing infrastructure costs 
which, along with orientation and training expenditures, were then added to capital 
expenditures to create estimated program expenses. Information from both data sets was 
used to create an Initial Financial Impact Analysis (see Appendix F).  
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Conclusion 
The reintroduction of a comprehensive CRA program within this clinical setting 
will add value to the community hospital and the medical group/provider network as well 
as enhance the level of patient/family centered care. The recommendation to the 
organization, based on data evaluation, is to conduct a complete financial analysis and 
business plan within a shared partnership, funded equally by the medical group and the 
hospital.  
To restate, the clinical value on quality outcomes of a program such as this is not 
the subject of debate. Rather, due to lack of interdepartmental communication, biases, 
and shifting clinical and organizational priorities the benefits of a future CRA program 
became undermined by the siloed nature of conflicting values. The requirement became 
to inject into the setting an advocate of the program and it’s outcomes with the intent to 
objectively assess the environment and it’s readiness for change; culturally, logistically, 
and financially. The role of the CNL student in this capacity has resulted in the 
demonstration of a valuable resource. The CNL student has been able to perform as 
patient advocate, systems and risk analyst, and outcomes manger, as well as a facilitator 
of communication to understand and verbalize common goals.  
In spite of the evolution of this project from a tangible program implementation to 
that of a value proposition, the shifting focus of this project highlights the dynamic nature 
of the health care environment. The skills learned by the CNL student have been in a real 
world context, with far reaching application toward future endeavors. 
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Appendix A 
SWOT Analysis 
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Single clinician (NP-GC) to 
manage CRA program 
Site staff unclear on    
their role in program 
End of grant funding led to shift in 
clinician function priorities 
Limited staff infrastructures resulting 
in inability to conduct pt. follow up 
Appendix B 
            Root Cause Analysis 
             Fishbone Diagram 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Elimination of the 
Cancer Risk 
Assessment Program 
People 
Environment 
Process 
Site 
MA functions primarily 
in clerical role 
Site staff resentful of increased 
duties with no input 
Pt. volume increases led to GC 
inability to maintain CRA 
Lack of interdepartmental 
support of program 
Lack of designated space 
to grow program 
Merger with SJH – shift in 
priorities and structures 
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Appendix C 
Cost-Benefit Analysis 
 
 
*Indicates benefit items quantified within the Initial Financial Impact Analysis (see 
Appendix F) 
 
 
 
 
 
 
 
 
 
 
Cost Item 
Part-Time 
0.4 FTE 
Full-Time (Incorporates Nurse Navigator Role) 
1.0 FTE 
Staffing RN NP RN NP 
Salary $41,000.00 $52,416.00 $104,000.00 $131,040.00 
Benefits N/A N/A $31,200.00 $39,312.00 
Training $1,000.00 $1,000.00 $1,000.00 $1,000.00 
Staffing Subtotal $42,000.00 $53,416.00 $136,200.00 $171,352.00 
Survivorship/GC provider time $3,000.00 $3,000.00 
Office Supplies $1,000.00 $1,000.00 
Software $1,500.00 $1,500.00 
Hardware $4,000.00 $4,000.00 
Startup Subtotal $9,500.00 $9,500.00 
Total $51,500.00 $62,916.00 $145,700.00 $180,852.00 
Benefit Item 
Increased early detection and diagnosis in patients of first or second cancers 
Increased identification and stratification of patients at risk for hereditary or sporadic cancer 
Increased treatment options in identified patients resulting in prevention and/or curable detection 
Increased patient volume into the organization by offering a comprehensive cancer risk assessment program 
*Increased downstream revenue related to enhanced screening/diagnostic/surgical procedures 
Increased patient satisfaction and retention related to concurrent implementation of the nurse navigator role in breast 
   biopsy 
*Cost offset through the use of a Nurse Practitioner in the new role through clinician billable time 
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Appendix D 
Gantt Chart Timeline 
May 29 – August 12, 2017 
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Appendix E 
Recommended Patient Flowchart – Future CRA Program 
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Appendix F 
Initial Financial Impact Analysis 
 
 
